{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T12:48:12Z","timestamp":1784465292695,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,10,9]],"date-time":"2013-10-09T00:00:00Z","timestamp":1381276800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s40261-013-0140-7","type":"journal-article","created":{"date-parts":[[2013,10,8]],"date-time":"2013-10-08T13:37:12Z","timestamp":1381239432000},"page":"913-919","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetic Comparisons of Bepotastine Besilate and Bepotastine Salicylate in Healthy Subjects"],"prefix":"10.1007","volume":"33","author":[{"given":"Kyoung-Ah","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,9]]},"reference":[{"issue":"10","key":"140_CR1","first-page":"1116","volume":"47","author":"M Kato","year":"1997","unstructured":"Kato M, Nishida A, Aga Y, et al. Pharmacokinetic and pharmacodynamic evaluation of central effect of the novel antiallergic agent betotastine besilate. Arzneimittelforschung. 1997;47(10):1116\u201324.","journal-title":"Arzneimittelforschung."},{"issue":"10","key":"140_CR2","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1185\/03007995.2010.486753","volume":"26","author":"JI Williams","year":"2010","unstructured":"Williams JI, Gow JA, Klier SM, et al. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Curr Med Res Opin. 2010;26(10):2329\u201338.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"140_CR3","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1398-9995.2008.01642.x","volume":"63","author":"J Bousquet","year":"2008","unstructured":"Bousquet J, Reid J, van Weel C, et al. Allergic rhinitis management pocket reference 2008. Allergy. 2008;63(8):990\u20136.","journal-title":"Allergy"},{"issue":"12","key":"140_CR4","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1345\/aph.1E638","volume":"39","author":"MM Morgan","year":"2005","unstructured":"Morgan MM, Khan DA, Nathan RA. Treatment for allergic rhinitis and chronic idiopathic urticaria: focus on oral antihistamines. Ann Pharmacother. 2005;39(12):2056\u201364.","journal-title":"Ann Pharmacother"},{"key":"140_CR5","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2147\/OPTH.S35431","volume":"6","author":"CF McCabe","year":"2012","unstructured":"McCabe CF, McCabe SE. Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference. Clin Ophthalmol. 2012;6:1731\u20138.","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"140_CR6","first-page":"1137","volume":"13","author":"H Yokota","year":"1997","unstructured":"Yokota H, Mizuuchi H, Maki T, et al. Phase I study of TAU-284: single oral administration in healthy male volunteers. J Clin Ther Med. 1997;13(5):1137\u201353.","journal-title":"J Clin Ther Med"},{"issue":"5","key":"140_CR7","first-page":"1155","volume":"13","author":"T Kadosaka","year":"1997","unstructured":"Kadosaka T, Shiraishi K, Mizuuchi H, et al. Phase I study of TAU-284: repeated oral administration in healthy male volunteers. J Clin Ther Med. 1997;13(5):1155\u201368.","journal-title":"J Clin Ther Med"},{"issue":"12","key":"140_CR8","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2165\/11205880-000000000-00000","volume":"70","author":"KA Lyseng-Williamson","year":"2010","unstructured":"Lyseng-Williamson KA. Oral bepotastine: in allergic disorders. Drugs. 2010;70(12):1579\u201391.","journal-title":"Drugs"},{"issue":"7","key":"140_CR9","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.clinthera.2011.05.089","volume":"33","author":"D Ha","year":"2011","unstructured":"Ha D, Choi Y, Kim DU, et al. A comparative analysis of the impact of a positive list system on new chemical entity drugs and incrementally modified drugs in South Korea. Clin Ther. 2011;33(7):926\u201332.","journal-title":"Clin Ther"},{"issue":"8","key":"140_CR10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1359-6446(05)03410-0","volume":"10","author":"SA Charles","year":"2005","unstructured":"Charles SA. SuperGenerics: a better alternative for biogenerics. Drug Discov Today. 2005;10(8):533\u20135.","journal-title":"Drug Discov Today"},{"issue":"6","key":"140_CR11","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3109\/03639045.2012.717295","volume":"39","author":"KH Cho","year":"2013","unstructured":"Cho KH, Choi HG. Development of novel bepotastine salicylate salt bioequivalent to the commercial bepotastine besilate in beagle dogs. Drug Dev Ind Pharm. 2013;39(6):901\u20138.","journal-title":"Drug Dev Ind Pharm"},{"key":"140_CR12","unstructured":"World Medical Association Declaration of Helsinki - ethical principles for medical research involving human subjects. http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html . Accessed 12 Feb 2013."},{"key":"140_CR13","unstructured":"ICH Harmonised Tripartite Guideline. Guideline for good clinical practice E6 (R1). http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6_R1\/Step4\/E6_R1__Guideline.pdf . Accessed 27 Jun 2013."},{"key":"140_CR14","unstructured":"Korea Food & Drug Administration. Guideline for the validation of bioanalytical method [in Korean]. http:\/\/drug.kfda.go.kr\/Data\/KO_DU\/20100804092704_0.hwp . Accessed 27 Jun 2013."},{"key":"140_CR15","first-page":"1","volume-title":"Design and analysis of bioavailability and bioequivalence studies","author":"SC Chow","year":"2000","unstructured":"Chow SC, Liu JP. Design and analysis of bioavailability and bioequivalence studies. 3rd ed. New York: Narcel Dekker; 2000. p. 1\u201330.","edition":"3"},{"issue":"1","key":"140_CR16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.12793\/jkscpt.2007.15.1.37","volume":"15","author":"BH Kim","year":"2007","unstructured":"Kim BH, Cung JY, Kim JR, et al. Pharmacokinetic characteristics of bepotastine besilate in healthy subjects. Korean J Clin Pharmacol Ther. 2007;15(1):37\u201345.","journal-title":"Korean J Clin Pharmacol Ther"},{"issue":"2","key":"140_CR17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1011503032353","volume":"28","author":"SC Chow","year":"2001","unstructured":"Chow SC, Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn. 2001;28(2):155\u201369.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"140_CR18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/BF01068419","volume":"15","author":"DJ Schuirmann","year":"1987","unstructured":"Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15(6):657\u201380.","journal-title":"J Pharmacokinet Biopharm"},{"key":"140_CR19","unstructured":"US Food and Drug Administration. Guidance for industry bioavailability and bioequivalence studies for orally administered drug products\u2014general considerations. Rockville: US Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug evaluation and Research (CDER); 2003."},{"issue":"5","key":"140_CR20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1124\/dmd.105.007559","volume":"34","author":"R Ohashi","year":"2006","unstructured":"Ohashi R, Kamikozawa Y, Sugiura M, et al. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate. Drug Metab Dispos. 2006;34(5):793\u20139.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"140_CR21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2174\/138945011795378487","volume":"12","author":"V Haufroid","year":"2011","unstructured":"Haufroid V. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. Curr Drug Targets. 2011;12(5):631\u201346.","journal-title":"Curr Drug Targets"},{"issue":"1","key":"140_CR22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2133\/dmpk.DMPK-11-RV-098","volume":"27","author":"I Ieiri","year":"2012","unstructured":"Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet. 2012;27(1):85\u2013105.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"7","key":"140_CR23","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.clinthera.2011.06.003","volume":"33","author":"KA Kim","year":"2011","unstructured":"Kim KA, Lim JL, Kim C, Park JY. Pharmacokinetic comparison of orally disintegrating and conventional donepezil formulations in healthy Korean male subjects: a single-dose, randomized, open-label, 2-sequence, 2-period crossover study. Clin Ther. 2011;33(7):965\u201372.","journal-title":"Clin Ther"},{"issue":"4","key":"140_CR24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5414\/CPP48291","volume":"48","author":"JY Park","year":"2010","unstructured":"Park JY, Kim KA, Lee YH, et al. Pharmacokinetic comparison and bioequivalence of two leflunomide formulations in humans: a single dose, randomized, open-label, two-way crossover study. Int J Clin Pharmacol Ther. 2010;48(4):291\u20135.","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0140-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-013-0140-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0140-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T13:38:02Z","timestamp":1596634682000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-013-0140-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,9]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["140"],"URL":"https:\/\/doi.org\/10.1007\/s40261-013-0140-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,9]]}}}